X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dr. Reddys with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs MYLAN (US) - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DR. REDDYS LAB   MYLAN
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-16
MYLAN
Dec-14
DR. REDDYS LAB/
MYLAN
5-Yr Chart
Click to enlarge
High Rs4,3833,824-   
Low Rs2,7502,695-   
Sales per share (Unadj.) Rs920.11,309.1-  
Earnings per share (Unadj.) Rs126.1157.7-  
Cash flow per share (Unadj.) Rs183.0253.8-  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs685.8650.7-  
Shares outstanding (eoy) m170.61378.37-   
Bonus/Rights/Conversions ESOPOI-  
Price / Sales ratio x3.92.5 155.7%   
Avg P/E ratio x28.320.7 136.8%  
P/CF ratio (eoy) x19.512.8 151.8%  
Price / Book Value ratio x5.25.0 103.8%  
Dividend payout %15.90-   
Avg Mkt Cap Rs m608,4811,233,232 49.3%   
No. of employees `00021.725.0 86.7%   
Total wages/salary Rs m31,8740-   
Avg. sales/employee Rs Th7,244.419,812.6 36.6%   
Avg. wages/employee Rs Th1,470.90-   
Avg. net profit/employee Rs Th992.82,386.8 41.6%   
INCOME DATA
Net Sales Rs m156,978495,315 31.7%  
Other income Rs m2,693-2,887 -93.3%   
Total revenues Rs m159,671492,428 32.4%   
Gross profit Rs m34,587123,187 28.1%  
Depreciation Rs m9,70536,379 26.7%   
Interest Rs m82421,365 3.9%   
Profit before tax Rs m26,75162,556 42.8%   
Minority Interest Rs m0-257 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,2372,631 199.1%   
Profit after tax Rs m21,51459,669 36.1%  
Gross profit margin %22.024.9 88.6%  
Effective tax rate %19.64.2 465.5%   
Net profit margin %13.712.0 113.8%  
BALANCE SHEET DATA
Current assets Rs m118,201435,448 27.1%   
Current liabilities Rs m68,368340,433 20.1%   
Net working cap to sales %31.719.2 165.5%  
Current ratio x1.71.3 135.2%  
Inventory Days Days6078 76.8%  
Debtors Days Days97107 90.3%  
Net fixed assets Rs m72,265114,590 63.1%   
Share capital Rs m85317,516 4.9%   
"Free" reserves Rs m111,5480-   
Net worth Rs m117,009246,220 47.5%   
Long term debt Rs m10,690367,829 2.9%   
Total assets Rs m200,104991,753 20.2%  
Interest coverage x33.53.9 852.0%   
Debt to equity ratio x0.11.5 6.1%  
Sales to assets ratio x0.80.5 157.1%   
Return on assets %11.28.2 136.6%  
Return on equity %18.424.2 75.9%  
Return on capital %21.613.6 158.5%  
Exports to sales %46.30-   
Imports to sales %9.00-   
Net fx Rs m48,2900-   
CASH FLOW
From Operations Rs m40,47665,110 62.2%  
From Investments Rs m-19,421-51,347 37.8%  
From Financial Activity Rs m-17,009-17,156 99.1%  
Net Cashflow Rs m4,046-3,394 -119.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.16 Rs / USD

Compare DR. REDDYS LAB With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare DR. REDDYS LAB With: WOCKHARDT LTD.  PLETHICO PHARMA  LUPIN LTD  SUVEN LIFE  ALKEM LABORATORIES  



Today's Market

Sensex Opens Flat; Infosys Down 4.1%(09:30 am)

Asian stock markets opened mixed in early trade today. Hong Kong Hang Seng has advanced 143 points and China's Shanghai Composite has gained 9 points.

Related Views On News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 21, 2017 11:11 AM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - LUPIN LTD COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS